The achilles heel of the CD12 trial-- Cytodyn
Post# of 148148
(Total Views: 527)
Posted On: 03/31/2021 11:01:54 PM
The achilles heel of the CD12 trial--
Cytodyn "seems to have uncovered the achilles heel of the CD12 trial. It was the dosing regimen and the FDA’s reluctance to allow more doses during the evaluation period that prevented the trial from being a knockout punch to the virus.
Common sense at the FDA level didn’t seem to prevail in the CD12 trial because the half life of leronlimab is only a week , and the patients were only injected twice which means the active drug was only in their body for 14 days. This ultimately leaves the patient without any treatment for the second half of the 28 day study time. All the other COVID-19 drugs were allowed large infusions. It’s unclear why the FDA took such a conservative stance with such a safe drug. "
https://emerginggrowth.com/cytodyn-otcqb-cydy...mortality/
And it's equally unclear why the Amarex people who knew very well about the half life of leronlimab agreed to toe the FDA line and doom the trial before it started!
Cytodyn "seems to have uncovered the achilles heel of the CD12 trial. It was the dosing regimen and the FDA’s reluctance to allow more doses during the evaluation period that prevented the trial from being a knockout punch to the virus.
Common sense at the FDA level didn’t seem to prevail in the CD12 trial because the half life of leronlimab is only a week , and the patients were only injected twice which means the active drug was only in their body for 14 days. This ultimately leaves the patient without any treatment for the second half of the 28 day study time. All the other COVID-19 drugs were allowed large infusions. It’s unclear why the FDA took such a conservative stance with such a safe drug. "
https://emerginggrowth.com/cytodyn-otcqb-cydy...mortality/
And it's equally unclear why the Amarex people who knew very well about the half life of leronlimab agreed to toe the FDA line and doom the trial before it started!
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼